New Joint Venture Launches Canine Lymphoma Test
A new canine lymphoma diagnostic kit can differentiate patients with lymphadenopathy due to lymphoma from ones with lymphadenopathy due to other ailments, such as lymphoid hyperplasia.
The Tri-Screen Canine Lymphoma Assay Kit is the first product to be offered by Tri-Screen—a new joint venture between Ireland-based animal diagnostic technology firm Tridelta Development Ltd. and animal cancer test developer Petscreen Ltd. of the U.K.
Petscreen developed the Advanced Lymphoma Blood Test on which the kit is based. The test combines relative values of the acute phase proteins haptoglobin and C-reactive protein in a patient’s blood serum into an analytical algorithm to determine if a patient’s lymphadenopathy is due to lymphoma or another ailment.
Petscreen enlisted support from veterinarians in the U.S. and the U.K. to test the method on samples from 194 canine patients with lymphoma, diseases with similar presentation to lymphoma, and healthy dogs.
Petscreen said it partnered with Tridelta because of the company’s reputation and experience with the international pharmaceutical industry in the niche sector of manufacturing and marketing acute phase protein diagnostic kits.